SCHEMBL211983

SCHEMBL211983

O=C(O)c1cccc(CCCCCCCCc2cccc(C(=O)O)c2C(=O)O)c1C(=O)O

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BID P55957 7/20 0.58
MCL1 Q07820 7/20 0.58
BCL2L1 Q07817 6/20 0.58
BAK1 Q16611 6/20 0.58
KAT8 Q9H7Z6 3/20 0.58
PPARA Q07869 3/20 0.58
PPARG P37231 2/20 0.58
SAE1 Q9UBE0 2/20 0.58
EP300 Q09472 2/20 0.58
KAT2B Q92831 2/20 0.58
KAT5 Q92993 2/20 0.58
KAT2A Q92830 1/20 0.58
FOLH1 Q04609 1/20 0.54
MMP2 P08253 2/20 0.50
F7 P08709 2/20 0.50
F3 P13726 2/20 0.50
KDM4E B2RXH2 1/20 0.50
MAPT P10636 1/20 0.50
ALOX15 P16050 1/20 0.50
ECE1 P42892 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9330418 1.00 BID (0.58) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL10885451 0.98 BID (0.56) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL5114102 0.94 FOLH1 (0.56) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL11052053 0.93 BID (0.53) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL3033684 0.92 BID (0.72) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL5424052 0.92 BID (0.72) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL5519496 0.92 BID (0.72) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL3258790 0.92 BID (0.72) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL23277 0.92 BID (0.72) BIDMCL1BCL2L1BAK1KAT8
SCHEMBL301487 0.92 BID (0.72) BIDMCL1BCL2L1BAK1KAT8

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8088405-B2 Therapeutic compositions and methods Rutgers, The State University of New Jersery (US) 2012-01-03 US disclosed
US-8017714-B2 Polyanhydrides with therapeutically useful degradation products RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2011-09-13 US disclosed
US-20100074937-A1 POLYANHYDRIDES WITH THERAPEUTICALLY USEFUL DEGRADATION PRODUCTS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2010-03-25 US disclosed
EP-1261347-B1 THERAPEUTIC COMPOSITIONS AND METHODS FOR TREATING PERIODONTITIS WITH ANTIINFLAMATORY COMPOUNDS UNIV RUTGERS (US) 2009-09-30 EP disclosed
EP-2095817-A1 Therapeutic compositions and methods RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2009-09-02 EP disclosed
US-7534852-B2 Polyanhydrides with therapeutically useful degradation products RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2009-05-19 US disclosed
EP-1032605-B1 POLYANHYDRIDES WITH THERAPEUTICALLY USEFUL DEGRADATION PRODUCTS UNIV RUTGERS (US) 2007-11-14 EP disclosed
US-20070213500-A1 Polyanhydrides with therapeutically useful degradation products RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2007-09-13 US disclosed
US-20070014832-A1 Therapeutic compositions and methods RUTGERS, THE STATE UNIVESITY OF NEW JERSEY 2007-01-18 US disclosed
US-7122615-B1 Polyanhydrides with therapeutically useful degradation products RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2006-10-17 US disclosed
EP-1246627-B1 POLYANHYDRIDES WITH BIOLOGICALLY ACTIVE DEGRADATION PRODUCTS UNIV RUTGERS (US) 2005-12-28 EP disclosed
US-20050249697-A1 Compositions and methods for the inhibition of bone growth and resorption RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2005-11-10 US disclosed
WO-2005039489-A2 COMPOSITIONS AND METHODS FOR THE INHIBITION OF BONE GROWTH AND RESORPTION POLYMERIX CORPORATION (US) 2005-05-06 WO disclosed
EP-1464673-A2 Polyanhydrides with biologically active degradation products RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2004-10-06 EP disclosed
US-20040038948-A1 Therapeutic compositions and methods UHRICH KATHRYN E (US) 2004-02-26 US disclosed
US-6685928-B2 ADMINISTERING AN EFFECTIVE AMOUNT OF AN ANTI-INFLAMMATORY AGENT TO OR NEAR THE TISSUE TO PROMOTE HEALING OF TISSUE; USEFUL IN DENTAL AND ORTHOPEDIC APPLICATIONS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2004-02-03 US disclosed
US-20030035787-A1 Polyanhydrides with biologically active degradation products RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2003-02-20 US disclosed
US-6468519-B1 DEPOLYMERIZATION OF BIOCOMPATIBLE TREATMENT AGENT PROVIDING ALPHAHYDROXYACIDS SUCH AS CITRIC ACID OR MALIC ACID; CREAMS, MOISTURIZERS, CLEANSERS, LOTIONS, SHAMPOOS, LIPSTICKS; SMOOTHER, CLEARER SKIN WITH FEWER WRINKLES RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY 2002-10-22 US disclosed
US-20020106345-A1 Therapeutic compositions and methods POLYMERIX CORPORATION 2002-08-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050249697-A1 Compositions and methods for the inhibition of bone growth and resorption SOST, BMP2, BMP1 BID 410/4885MCL1 479/4885BCL2L1 390/4885
US-20020106345-A1 Therapeutic compositions and methods COL2A1, BMP2, BMP4 BID 3492/4885MCL1 1278/4885BCL2L1 644/4885
US-20070014832-A1 Therapeutic compositions and methods COL2A1, BMP2, BMP4 BID 3492/4885MCL1 1278/4885BCL2L1 644/4885
US-20040038948-A1 Therapeutic compositions and methods COL2A1, BMP2, BMP4 BID 3492/4885MCL1 1278/4885BCL2L1 644/4885
US-20100074937-A1 POLYANHYDRIDES WITH THERAPEUTICALLY USEFUL DEGRADATION PRODUCTS AADAT, PAH, APEH BID 1198/4885MCL1 4410/4885BCL2L1 3588/4885
US-20030035787-A1 Polyanhydrides with biologically active degradation products SI, HAAO, GUSB BID 3896/4885MCL1 3110/4885BCL2L1 3740/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.